Drug to slow aortic stenosis shows early promise
Research we're watching
- Reviewed by Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, Harvard Health Publishing
A new investigational medication may safely slow the progression of aortic stenosis (narrowing of the aortic valve) and delay the need for valve replacement, according to a small study published in the April 2025 issue of Circulation.
The drug, called ataciguat, works by binding to molecules that drive calcification within the valve. For the trial, 46 people with aortic stenosis were randomly assigned to receive ataciguat or a placebo for six months. Imaging tests revealed a reduction of nearly 70% in the progression of aortic valve calcification among those taking the drug compared to those on a placebo. People on the drug also showed improved heart function, including preserved pumping ability.
If future planned trials confirm these findings and the drug is approved, it would be the first medication available to treat aortic stenosis.
Image: © The Good Brigade /Getty Images
About the Author
Julie Corliss, Executive Editor, Harvard Heart Letter
About the Reviewer
Christopher P. Cannon, MD, Editor in Chief, Harvard Heart Letter; Editorial Advisory Board Member, Harvard Health Publishing
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
